Meetings of Nobel Laureates Lindau from Jessica Riccò, 28. June 2010, 18:25 The late morning in Lindau was a non-stop marathon of medical researchers – first Harald zur Hausen talked about the links between infections and cancer, then Luc Montagnier gave an insight into his research that analyzes DNA under physical as well as biological […]
Assessing the effectiveness of human papillomavirus (HPV) vaccination to prevent cervical cancer: perspectives from Germany
J Epidemiol Community Health
February 2010 Vol 64 No 2
For approximately 2 years now, cervical cancer has been “converted” from an oncological disease to an infectious disease, which is said to be preventable by and large by two vaccines licensed in many countries. However, human papillomavirus (HPV) vaccines differ from existing others, as the former target
a condition which only in a minute fraction of infections will lead to serious consequences, but after a long(er) latency period. Furthermore, it should be kept in mind that in clinical trials, the quadrivalent vaccine was tested in fewer than 1200 girls 16 years and younger.1
Parents Warn of HPV Vaccine Dangers
The Epoch Times
By Susanne Larsson
Epoch Times Staff
Sweden
Despite thousands of young girls’ accounts of severe side effects from Gardasil injections, the manufacturer, Merck & Co, Inc., continues to make and sell the vaccine, which is supposed to protect against cervical cancer. Now the girls’ parents warn about the vaccine on their own websites.
According to Natural News Magazine, the Food and Drug Administration (FDA) approved Gardasil for the American market in 2006, and by February 2009, more than 40 million doses had been distributed worldwide.
Gardasil is a vaccine that’s supposed to prevent cervical cancer caused by the human papilloma virus (HPV). The virus spreads through sexual intercourse or skin contact.
Inovio Pharmaceuticals Achieves Unprecedented T-Cell Immune Responses in Human Trial of DNA Vaccine for Cervical Dysplasia and Cancer Caused by HPV
DNA Vaccine Delivered Using Electroporation Shows Potential to Treat Cervical Cancer and Precursor Dysplasias; Vaccine to Start Phase II in Early 2011
Market Watch
BLUE BELL, Pa., Sep 13, 2010 (BUSINESS WIRE) — Inovio Pharmaceuticals, Inc. /quotes/comstock/14*!ino/quotes/nls/ino (INO 1.11, 0.00, 0.00%) , a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that it has achieved best-in-class immune responses in its Phase I dose escalation study of VGX-3100, its DNA vaccine to treat pre-cancerous cervical dysplasias and cervical cancers caused by human papillomavirus (HPV) types 16 and 18. This vaccine targets HPV E6 and E7 proteins and is delivered via in vivo electroporation. All dose groups developed significant antibody and T-cell immune responses; however, more notably, in the third and final dose group, five of six (83%) patients developed unprecedented T-cell responses not achieved by any other non-replicating vaccine platform in humans. Inovio is planning to start a Phase II clinical study in the first quarter of 2011.
Gardasil and Seizures: is VAERS now taking a connection seriously?
Gardasil Side Effects
September 13, 2010
Theresa E was floored when she got a phone call from VAERS, the FDA’s vaccine adverse event reporting system. Yes, the caller said, investigators did indeed feel that Theresa’s daughter’s seizures could be a serious reaction to Merck’s anti-HPV vaccine, Gardasil.
Although Theresa had had a hunch that her daughter’s intermittent seizures could have been triggered by the Gardasil vaccine, doctors completely pooh-poohed the idea.
But eventually, encouraged by information from Nina Kenney, whose daughter had also begun suffering seizures post-vaccine, she insisted on filing a VAERS report. Her doctor had for months been “too busy” to get around to the paperwork, she said, “and when I took the almost-completed form to him to finish he was a little shocked that I was serious.”
- « Previous Page
- 1
- …
- 18
- 19
- 20
- 21
- 22
- …
- 25
- Next Page »